Everolimus-Eluting Platinum Chromium Coronary Stent System
Now CE Marked
The SYNERGY Stent is designed so its attributes synergistically work together to promote optimal healing within the vessel.1
Because you never know when life will become complex
Drug-eluting stent technology has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis and revascularization procedures. Still, there remains a concern for being able to treat ever-increasing complex lesions, ensuring proper healing, and managing dual antiplatelet therapy (DAPT).
What if there was a technology that offered the benefits of being able to improve the ability to acutely treat complex lesions, improve the healing properties, and potentially free selected patients from long-term DAPT?**
Introducing the SYNERGY Stent
Designed to help patients, including those with complex cases, heal from day one and beyond.
Designed to Heal
Abluminally-coated stent technology synchronizes the release of drug elution and polymer absorption for optimal healing within the vessel.1Learn more
The SYNERGY Stent’s ultra-thin struts show more rapid healing compared to thicker stent strut designs in clinical cases and in preclinical research.2,3Learn more
Freedom from Long-Term Polymer Exposure
Polymer is gone when it’s no longer needed—shortly after the drug is completely eluted at three months, which minimizes polymer exposure in the vessel.4Learn more
SYNERGY Stent Clinical Program and Research
Addressing the full spectrum of cardiovascular disease complexity
The SYNERGY Stent design goals are to address needs surrounding complex PCI. As a result, Boston Scientific established a robust clinical trial program and is supporting investigator-sponsored research5 (ISR) that will study the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice.
Not yet a member of the Complex PCI Community?
In selected higher risk patients where the physician determines that the risks outweigh the benefits of continued DAPT, it may be reasonable to interrupt or discontinue therapy after 1 month based on low stent thrombosis rates and no observed increased risk for stent thrombosis as shown in the current literature. Patients who require premature discontinuation of antiplatelet therapy should be monitored closely and have their antiplatelet therapy restarted as soon as possible per the discretion of their treating physicians.